Expression of the murine complement regulatory protein Crry by glial cells and neurons

GLIA

Volumn 27, Issue 2, 1999, Pages 162-170

  Davoust, Nathalie ^a   Nataf, Serge ^a   Holers, V Michael ^b   Barnum, Scott R ^a,c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

Astrocytes; Crry; Microglia; Murine; Neurons

Indexed keywords

COMPLEMENT; MURINE COMPLEMENT REGULATORY PROTEIN; NERVE CELL; PROTEIN EXPRESSION;

ANIMALS; ASTROCYTES; BLOTTING, WESTERN; COMPLEMENT ACTIVATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; IN SITU HYBRIDIZATION; MICE; MICE, INBRED C57BL; MICROGLIA; NERVE TISSUE PROTEINS; NEURONS; RECEPTORS, COMPLEMENT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0033178257     PISSN: 08941491     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-1136(199908)27:2<162::AID-GLIA6>3.0.CO;2-K     Document Type: Article

References (31)

1. Bottenstein JE, Sato GH. 1979. Growth of rat neuroblastoma cell line in serum-free supplemented medium. Proc Natl Acad Sci USA 76:514-517.
2. Davoust N, Nataf S, Holers MV, Berthiaume D, Campbell IL, Barnum SR. 1998. Development of transgenic mice with astroeyte-targeted expression of a soluble inhibitor of complement. J Neuroimmunol 90:47A.
3. Foley S, Li B, Dehoff M, Molina H, Holers VM. 1993. Mouse Crry/p65 is regulator of the alternative pathway of complement activation. Eur J Immunol 23:1381-1384.
4. Gasque P, Morgan BP. 1996. Complement regulatory protein expression by a human oligodendrocyte cell line: cytokine regulation and comparison with astrocytes. Immunology 89:338-347.
5. Holers VM, Kinoshita T, Molina H. 1992. The evolution of mouse and human complement C3-binding proteins: divergence of form but conservation of function. Immunol Today 13:231-236.
6. Hourcade D, Holers VM, Atkinson JP. 1989. The regulators of complement activation (RCA) gene cluster. Adv Immunol 45:381-416.
7. Kendall G, Crankson H, Ensor E, Lublin DM, Latchman DS. 1996. Activation of the gene encoding decay accelerating factor following nerve growth factor treatment of sensory neurons is mediated by promoter sequences within 206 bases of the transcriptional start site. J Neurosci Res 45:96-103.
8. Kim Y-U, Kinoshita T, Molina H, Hourcade D, Seya T, Wagner LM, Holers VM. 1995. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J Exp Med 181:151-159.
9. Li B, Sallee C, Dehoff M, Foley S, Molina H, Holers VM. 1993. Mouse Crry/p65. Characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF. J Immunol 151:4295-4305.
10. Liszewski MK, Atkinson JP. 1998. Regulatory proteins of complement. In: Volanakis JE, Frank MM, editors. The human complement system in health and disease. New York: Marcel Dekker. p 149-165.
11. McCarthy KD, de Vellis J. 1980. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 85:890-902.
12. Morgan BP, Gasque P. 1996. Expression of complement in the brain: Role in health and disease. Immunol Today 17:461-466.
13. Nangaku M, Quigg RJ, Shankland SJ, Okada N, Johnson RJ, Couser WG. 1997. Overexpression of Crry protects mesangial cells from complement-mediated injury. J Am Soc Nephrol 8:223-233.
14. Nicholson-Weller A, Burge J, Fearon DT, Weller PF, Austen KF. 1982. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol 129:184-189.
15. Paul MS, Aegerter M, O'Brien SE, Kurtz CB, Weis JH. 1989. The murine complement receptor gene family. Analysis of mCRY gene products and their homology to human CR1. J Immunol 142:582-589.
16. Post TW, Liszewski MK, Adams EM, Tedja I, Miller EA, Atkinson JP. 1991. Membrane cofactor protein of the comeplement system: alternative splicing of serine/threonine/proline-rich exons and cytoplasmic tails produces multiple isoforms that correlate with protein phenotype. J Exp Med 174:93-102.
17. Quigg RJ, Holers VM. 1995. Characterization of rat complement receptors and regulatory proteins. CR2 and Crry are conserved, and the C3b receptor of neutrophils and platelets is distinct from CR1. J Immunol 155:1481-1488.
18. Quigg RJ, Lo CF, Alexander JJ, Sneed AE, Moxley G. 1995. Molecular characterization of rat Crry: widespread distribution of two alternative forms of Crry mRNA. Immunogenetics 42:362-367.
19. Quigg RJ, Kozono Y, Berthiaume D, Lim A, Salant DJ, Weinfeld A, Griffin P, Kremmer E, Holers VM. 1998. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J Immunol 160:4553-4560.
20. Rey-Campos J, Rubinstein P, Rodriguez de Cordoba. 1988. A physical map of the human regulator of complement activation gene cluster linking the complement genes CR1, CR2, DAF and C4BP. J Exp Med 167:664-669.
21. Rogers CA, Gasque P, Piddlesden SJ, Okada N, Holers VM, Morgan BP. 1996. Expression and function of membrane regulators of complement on rat astrocytes in culture. Immunology 88:153-161.
22. Scolding NJ, Morgan BP, Compston DA. 1998. The expression of complement regulatory proteins by adult human oligodendrocytes. J Neuroimmunol 84:69-75.
23. Seya T, Turner JB, Atkinson JP. 1986. Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. J Exp Med 163:837-855.
24. Shin ML, Rus H, Niculescu F. 1998. Complement system in central nervous system disorders. In: Volanakis JE, Frank MM, editors. The complement system in health and disease. New York: Marcel Dekker. p 499-525.
25. Spiegel K, Emmerling MR, Barnum SR. 1997. Strategies for inhibition of complement activation in the treatment of neurodegenerative diseases. In: Wood F, editor. Neurodegeneration: inflammatory mechanisms and management. Totowa, NJ: Humana Press. p 129-176.
26. Spiller OB, Moretto G, Kim SU, Morgan BP, Devine DV. 1996. Complement expression on astrocytes and astrocytoma cell lines: Failure of complement regulation at the C3 level correlates with very low CD55 expression. J Neuroimmunol 71:97-106.
27. Stahel PF, Frei K, Eugster H-P, Fontana A, Hummel KM, Wetsel RA, Ames RS, Barnum SR. 1997. TNF-a-mediated expression of the receptor for anaphylatoxin C5a on neurons in experimental Listeria meningocephalitis. J Immunol 159:861-869.
28. Stalder AK, Carson M, Pagenstecher A, Asensio VC, Kincaid C, Benedict M, Powell HC, Masliah E, Campbell IL. 1998. Late-onset chronic inflammatory encephalopathy in immune-competent and severe combined immunodeficient (SCID) mice with astrocyte-targeted expression of tumor necrosis factor. Am J Pathol 153:767-783.
29. Tanaka M, Marunouchi T, Sawada M. 1997. Expression of Ly-6C on microglia in the developing and adult mouse brain. Neurosci Lett 239:17-20.
30. Yang C, Jones JL, Barnum SR. 1993. Expression of decay-accelerating factor (CD55), membrane cofactor protein (CD46) and CD59 in the human astroglioma cell line, D54-MG, and primary rat astrocytes. J Neuroimmunol 47:123-132.
31. Zhang KZ, Junnikkala S Erlander MG, Guo H, Westberg JA, Meri S, Andersson LC. 1998. Up-regulated expression of decay-accelerating factor (CD55) confers increased complement resistance to sprouting neural cells. Eur J Immunol 28:1189-1196.